Fast Market Research announces the availability of the new Global Markets Direct report, "Alzheimer's Disease - Pipeline Review, H1 2016", on their comprehensive research portal
Boston, MA -- (SBWIRE) -- 05/04/2016 -- Global Markets Direct's, 'Alzheimer's Disease - Pipeline Review, H1 2016', provides an overview of the Alzheimer's Disease pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Alzheimer's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects.
Get More Details on this Report and a Full Table of Contents at Alzheimer's Disease - Pipeline Review, H1 2016
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
-The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease
-The report reviews pipeline therapeutics for Alzheimer's Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved Alzheimer's Disease therapeutics and enlists all their major and minor projects
-The report assesses Alzheimer's Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
-The report summarizes all the dormant and discontinued pipeline projects
-The report reviews latest news related to pipeline therapeutics for Alzheimer's Disease
Reasons to Get this Report
-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease
-Identify potential new clients or partners in the target demographic
-Develop strategic initiatives by understanding the focus areas of leading companies
-Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
-Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned in this Report: AB Science SA, AbbVie Inc., AC Immune SA, Accera, Inc., Acelot, Inc., Actinogen Limited, Acumen Pharmaceuticals, Inc., Addex Therapeutics Ltd, Affibody AB, AFFiRiS AG, Alector LLC, Alkermes Plc, ALSP, Inc., Alzhyme Pty Ltd, Alzinova AB, AlzProtect SAS, Amarantus Bioscience Holdings, Inc., Amgen Inc., Anavex Life Sciences Corp., Aphios Corporation, Apodemus AB, Applied Research using OMIC Sciences, S.L., Araclon Biotech, S.L., Archer Pharmaceuticals, Inc., ArmaGen Inc., Artery Therapeutics, Inc., AskAt Inc., Astellas Pharma Inc., AstraZeneca Plc, Asubio Pharma Co., Ltd., Ausio Pharmaceuticals, LLC, Avineuro Pharmaceuticals, Inc., Axerion Therapeutics, Inc., Axon Neuroscience SE, Axovant Sciences Ltd., Axsome Therapeutics, Inc., Axxam SpA, Beactica AB, Berg LLC, BioArctic Neuroscience AB, Bioasis Technologies Inc., Biogen, Inc., Biomar Microbial Technologies, Bionature E.A. Ltd., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Bsim2, Cardax Pharmaceuticals, Inc., Celon Pharma Sp. z o.o., CHA Bio & Diostech Co., Ltd., Chase Pharmaceuticals Corporation, Chong Kun Dang Pharmaceutical Corp., Clera Inc., Cognition Therapeutics, Inc., Cognosci, Inc., CohBar, Inc., CoLucid Pharmaceuticals, Inc., Connexios Life Sciences Pvt. Ltd., Corium International, Inc., Coronis Partners Ltd., Critical Outcome Technologies Inc., Crossbeta Biosciences B.V., D-Pharm Ltd., Daewoong Pharmaceutical Co., Ltd., Daval International Limited, DermaXon, LLC, Domain Therapeutics SA, Eisai Co., Ltd., Eli Lilly and Company, EncephRx, Inc., ENKAM Pharmaceuticals A/S, Ensemble Therapeutics Corporation, Ensol Biosciences Inc., Epigen Biosciences, Inc., Euroscreen S.A., Evotec AG, F. Hoffmann-La Roche Ltd., FORUM Pharmaceuticals Inc., Genentech, Inc., Genervon Biopharmaceuticals, LLC, GlaxoSmithKline Plc, GliaCure Inc., Golden Biotechnology Corp., Grifols, S.A., H. Lundbeck A/S, Heptares Therapeutics Limited, Herantis Pharma Plc, Humanetics Corporation, Ichor Medical Systems, Inc., Icure Pharmaceutical Inc., Immungenetics AG, Immunome Inc., Impel NeuroPharma, Inc., ImStar Therapeutics Inc., Inovio Pharmaceuticals, Inc., IntelGenx Corp., Intellect Neurosciences, Inc., Intra-Cellular Therapies, Inc., INVENT Pharmaceuticals, Inc., Io Therapeutics, Inc., Iproteos S.L., Jeil Pharmaceutical Co., Ltd., Jiangsu Kanion Pharmaceutical Co., Ltd., Johnson & Johnson, K-Stemcell Co., Ltd., Kadmon Corporation, LLC, Kalgene Pharmaceuticals Inc., Kareus Therapeutics, SA, KineMed, Inc., Kyowa Hakko Kirin Co., Ltd., Lead Discovery Center GmbH, Les Laboratoires Servier SAS, Lipopharma Therapeutics SL, Living Cell Technologies Limited, Lupin Limited, M3 Biotechnology, Inc., ManRos Therapeutics, MedDay, Medestea Research & Production S.p.A., MedImmune, LLC, Medisyn Technologies, Inc., Merck & Co., Inc., Merz Pharma GmbH & Co. KgaA, Metabolic Solutions Development Company, LLC, Mithridion, Inc., NAL Pharmaceuticals Ltd., Nanomerics Ltd, Nanotherapeutics, Inc., Neuralstem, Inc., Neuraltus Pharmaceuticals, Inc., Neurim Pharmaceuticals Ltd, Neurodyn Inc., NeuroGeneration, Inc., NeuroGenetic Pharmaceuticals, Inc., NeuroNascent, Inc., Neuronax SAS, NeurOp, Inc, NeuroPhage Pharmaceuticals, Inc., Neuropore Therapies, Inc., Neurotez, Inc., New World Laboratories, Inc., nLife Therapeutics, S.L., NLS Pharma Group, Novartis AG, Oligomerix, inc., Oryzon Genomics S.A., P2D Bioscience, Pain Therapeutics, Inc., Palumed S.A., Panacea Pharmaceuticals, Inc., PeptiDream Inc., Peptron, Inc., Pfizer Inc., PharmaKure Limited, PharmatrophiX, Inc., Pharmaxis Limited, Pharnext SAS, Pivot Pharmaceuticals Inc, Plexxikon Inc., Prana Biotechnology Limited, Probiodrug AG, Progenra, Inc., Proteome Sciences Plc, Proteostasis Therapeutics, Inc., Prothena Corporation Plc, QR Pharma, Inc., Radius Health, Inc., Regenera Pharma Ltd., reMYND NV, Resverlogix Corp., Sage Therapeutics, Inc., SanBio, Inc., Saneron CCEL Therapeutics, Inc., Saniona AB, Sanofi, SeneXta Therapeutics SA, Serometrix, LLC, SignPath Pharma Inc, Simcere Pharmaceutical Group, SK Biopharmaceuticals Co., Ltd., SOM Innovation Biotech SL, Spectrum Pharmaceuticals, Inc., Stemedica Cell Technologies, Inc., Sumitomo Dainippon Pharma Co., Ltd., Summit Therapeutics Plc, Suven Life Sciences Ltd., Takeda Pharmaceutical Company Limited, TauRx Therapeutics Ltd., TechnologieAllianz e. V., TechnoPhage SA, Tetra Discovery Partners LLC, Therapix Biosciences Ltd, Toyama Chemical Co., Ltd., Transition Therapeutics Inc., Treventis Corporation, TyrNovo Ltd., UCB S.A., Varinel, Inc., Virobay Inc., Vitae Pharmaceuticals, Inc., Vivus, Inc., vTv Therapeutics LLC, Vybion, Inc., Wellstat Therapeutics Corporation
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Drug Pipeline research reports at Fast Market Research
You may also be interested in these related reports:
-Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2016
-Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2016
-Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2016
-Sepsis - Pipeline Review, H1 2016
-Degenerative Disc Disease - Pipeline Review, H1 2016